By Daniella Parra Iovance Biotherapeutics said Amtagvi had a 52% response rate with two or less prior therapies and 73% overall disease control rate when used earlier in the treatment for advanced melanoma. Amtagvi is a one-time T cell therapy...

By Karen Roman GlucoTrack, Inc. (Nasdaq: GCTK) said the U.S. Patent and Trademark Office issued three patents for its continuous blood glucose monitoring platform as the company moves toward commercializing it. The three patents protect key technologies related to proprietary...

By Karen Roman Nano-X Imaging Ltd. (Nasdaq: NNOX) said it is collaborating with medical device distributor Adriamed to deploy the Nanox.ARC, a digital tomosynthesis system, to healthcare providers across Serbia, Montenegro, and Bosnia and Herzegovina. Adriamed will be Nanox’s exclusive...

By Karen Roman Ascentage Pharma Group Internat (Nasdaq: AAPG) said its treatment candidate for B-cell diseases APG-3288 was granted the investigational new drug clearance by the FDA. The company will also conduct a global Phase I study evaluating APG-3288 in...

By Karen Roman Biopharmaceutical company Medera Inc. said it completed patient enrollment for Cohort B of its clinical trial evaluating SRD-002 gene therapy for heart failure with preserved ejection fraction (HFpEF). This milestone allows Medera to advance to Phase 2b...

By Karen Roman SkylineDx said it published new peer-reviewed data where its Merlin CP-GEP Test outperforms the competition and current standards of care for identifying melanoma risk using molecular testing. In response to a competitor’s study comparing its own test...

By Karen Roman Sequana Medical NV (BRU: SEQUA.BR) said it successfully implanted the alfapump device for treatment of recurrent or refractory ascites due to liver cirrhosis in two patients at the University of Pennsylvania. The alfapump is the first FDA-approved...

By Daniella Parra March Bio is developing MB-105, a first-in-class autologous CD5-targeted CAR-T cell therapy for relapsed/refractory T-cell lymphoma and other CD5-positive hematologic malignancies, they said. The company said the therapy employs a proprietary CAR design that enables selective targeting of...

Exec Edge hosted a fireside chat on Dec. 8 from the Nasdaq Marketsite with Chris Searles, co-founder and Chief Executive Officer, and Trevor Smith, co-founder and Chief Technology Officer of DxCheck. The in-person interview was joined by Editor-in-Chief John Jannarone and...

IPO Edge hosted a fireside chat on Dec. 8 from the Nasdaq Marketsite with Christer Rosen, Chairman and Chief Executive Officer, and Alison Silva, President and Chief Business Officer of Jupiter Neurosciences, Inc. (Nasdaq: JUNS). The in-person interview was joined by...